All research articles
97 articles, newest first. Browse with images and search on the research page.
2026
- FDA Biosimilar Approvals Through Q3 2026 and Their Competition
- Every FDA Oncology Approval Notice in October 2026
- How to Build an Indication-Level Competitive Landscape
- Four Alzheimer Drug Readouts to Watch at CTAD 2026
- Q3 2026 CBER Approvals for Direct Patient Use
- Two Phase 3 CLDN18.2 ADC Readouts at ESMO 2026
- WCLC 2026 SCLC Phase 3 Results: Two B7-H3 ADCs and MAVERICK
- Q3 2026 Nasdaq Drug-Developer IPOs Above $100 Million
- Shifts in Pharma Revenue Mix Across Leading Portfolios: 2019-2024
- Clinical-Stage KRAS Therapeutics: How G12D and Pan-KRAS Strategies Are Reshaping Drug Development
- Biopharma Launch Activity: New Molecular and Biologic Entities, 2021–2025
- FDA Drug Approvals in 2025: What the Year’s 46 New Therapies Reveal About Industry Direction
- Big Pharma M&A in 2025: A Shift Toward De-Risked Growth
- Capital Efficiency in Chinese Biotech: A Comparative Analysis of Licensing Deal Structures
- U.S. Pharma Manufacturing and R&D Site Investments Announced in 2025
2025
- Best-Selling Immunology Drugs in Q3 2025: Revenue Leaders and Market Dynamics
- Beyond Insulin: Emerging Disease-Modifying Therapies in Type 1 Diabetes
- Top Pharmaceutical R&D Spending in 2025: How Big Pharma Is Allocating Capital Through Nine Months
- A New Era in Duchenne Muscular Dystrophy: Disease-Modifying Therapies in Development
- The Best-Selling Neurology Drugs in Q3 2025: Where Multibillion-Dollar Franchises Are Taking Shape
- The Next Generation of Chronic Spontaneous Urticaria Treatments: Targets, Approvals, and Pipeline Momentum
- Inside Big Pharma Portfolios Part 2: What Drove Revenue in Q3 2025
- Johnson and Johnson Q3 2025 Earnings: Oncology and Immunology Drive Growth After Strategic Reset
- Advancing Beyond Statins: Emerging Cholesterol-Lowering Medicines Reshaping Lipid Management
- AbbVie Q3 2025 Earnings: Skyrizi and Rinvoq Drive Post-Humira Growth
- Market Capitalization Trends of Leading Pharmaceutical Companies in 2025
- Pfizer Q3 2025 Earnings Analysis: Portfolio Rebalancing Amid COVID Decline and Upcoming LOEs
- HER2-Targeted Therapies Across Solid Tumors: Treatment Expansion and Earlier-Line Adoption in 2025
- Merck Q3 2025 Earnings Breakdown: Keytruda Dominance, Vaccine Softness, and Pipeline Diversification
- Inside Big Pharma's Portfolios: What Drove Q3 2025 Revenue
- 2025 Stock Performance of Top Pharmaceutical Companies: January 2–December 1
- Advancing Beyond Statins: The Landscape of Emerging Cholesterol-Lowering Medicines
- Gilead’s Q2 2025 Highlights
- AI Tools for Life Sciences Investment Banking: A Diligence Workflow
- US Biotech IPOs: H1 2025 Performance Update
- AI Platforms for Biotech and Pharmaceutical Equity Research
- J&J’s Q2 2025 Highlights: Innovative Medicine Drives Growth Despite Stelara Slowdown
- AI Platforms for Biotech and Pharmaceutical Consulting
- Merck’s $10B Verona Acquisition: Ohtuvayre Leads Next-Gen COPD Innovation
- AI Tools for Pharma Market Research: Choosing a Workflow
- Who will transform the HAE Market?
- Bladder Cancer: Emerging Therapies and Key Areas to Watch
2024
- Dato-DXd: AstraZeneca and Daiichi Sankyo's Unwavering ADC Pursuit
- The Radiopharmaceutical Revolution
- Biotech Funding from Private Rounds to IPO: Bicara, Zenas and MBX in 2024
- Top 10 Biopharma Companies by Market Cap: September 2023 vs. 2024
- Biotech IPO Trifecta: A Resurgence of Innovation and Investment
- Post-Keytruda: Potential Growth Drivers for Merck
- ESMO 2024: Recap of Notable Advances in Oncology
- Select Eli Lilly U.S. Patent Expiries
- Moderna's Strategic Shift: Paving the Way for Diversification and Profitability
- Q2 2024 Revenue and Growth Across Ten Major Biopharma Companies
- Pfizer Delivers Robust Q2 2024 Performance, Raises Full-Year Guidance
- Roche's Pharmaceutical Division Performance in Q2 2024 YoY
- Notable Biopharma Fundraises in August: Powering Promising Treatments
- Epidemiologies of Oncology: Insights from AstraZeneca and Novartis
- New EMA Medicine Approvals Through August 2024
- Revolutionizing Cancer Treatment: The Emergence of mRNA Vaccines
- Crowning Achievements: Recent Royalty Deals in BioPharma
- BioPharma's Direct-to-Consumer Evolution
- Atopic Dermatitis Landscape
- How Much Do Large BioPharma Companies Spend on Capex?
- Q2 2024 Sales of 15 Immunology Medicines
- Top 10 BioPharma Companies by Revenue Q2 2024
- Top 15 Oncology Medicines by Q2 2024 Sales
- Roche: 10 Year Sales Evolution
- Top 10 Medicines by Reported Q2 2024 Sales
- IRA's First 10: How Much Revenue is at Stake?
- Alzheimer's Disease Landscape
- Lilly and Novo: How do GLP-1 Sales Compare? (Q2 '24)
- AstraZeneca's Top 10 Medicines by Sales in Q2 '24
- Sanofi Revenue by Category - Q2 '24 Earnings Recap
- BMS Top 10 Medicines by Sales in Q2 '24
- Top 10 BioPharma Companies by Revenue (2003 to 2023)
- AbbVie Q2 Earnings: Immunology Strength Overshadows Aesthetics Challenges
- The Shifting Spending Priorities of Big Pharma
- The Prize of the Eyes: Eylea & Vabysmo in Opthalmology
- J&J's Q2 Earnings and Key Milestones in Immunology and Oncology
- Small Molecule GLP-1 Overview
- Recap of Recent Radiopharmaceutical Deals
- The Constant Evolution of Biopharma: A Decade of Transformation
- Q1 2024 Sales of 15 Immunology Medicines
- Novartis Navigates Patent Cliff with Robust Pipeline and Strategic Focus
- Top 10 Private Biopharma Financings in April 2024
- Large Pharma M&A: Comparing Disclosed Deal Values in 2022–2023
- Top 15 Biopharma Companies by Oncology Sales
- The 15 Biggest Biotech and Pharma Fundraisings in Q1 2024
- Top 10 Pharma Companies by Revenue in 2023
- Upcoming Patent Expirations and LOEs for the 15 Biggest Drugs by Sales
- Major Biopharma M&A Deals in Q1 2024
- 2023 Sales of Major Oncology Medicines
- Top 10 Immunology Drugs by Worldwide Sales in 2023
- Top 15 Drugs by Worldwide Sales in 2023
- Race for GLP-1 Obesity Drugs Heats Up
- How Drug Pricing in the US Compares to Other Countries
- AI Drug Discovery Continues to Show Strength, but Some Win More Than Others
- Big Pharma Partnerships in 2023: A Comprehensive Overview